Neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Alzheimer's Disease continue to pose major scientific, clinical, and societal challenges. At the same time, unprecedented advances in molecular biology, drug discovery, biomarkers, precision medicine, and advanced therapeutic approaches are transforming the landscape of neurological research and care.
This round table will bring together leading experts from academia, biotechnology, and clinical practice to discuss the latest innovations driving the development of next-generation therapies for neurodegenerative disorders. The discussion will explore emerging therapeutic strategies, including novel small molecules, biologics, regenerative and gene-based approaches, as well as the critical role of translational research in accelerating their path to patients.
Participants will examine how cutting-edge discoveries are being validated through clinical studies and real-world evidence, addressing key challenges related to efficacy assessment, biomarker development, patient stratification, regulatory pathways, and long-term outcomes. Particular attention will be given to lessons learned across ALS, MS, and Alzheimer's disease, highlighting opportunities for cross-disciplinary collaboration and innovation.
Featuring insights from Adolfo López de Munain, representatives of Golden Gait Biotech and CIC bioGUNE, and Ana Martínez Gil, the session will provide a comprehensive perspective on how scientific breakthroughs are advancing from the laboratory to clinical validation and, ultimately, to improved patient outcomes.
Key themes:- Advanced therapeutic approaches for ALS, MS, and Alzheimer's disease
- Translational pathways from discovery to clinical application
- Biomarkers and patient stratification for precision neurology
- Clinical trial innovation and real-world evidence generation
- Collaboration between academia, healthcare systems, and biotech companies
- Future opportunities and challenges in neurodegenerative disease treatment development
This discussion will offer attendees a unique opportunity to gain insights into the evolving neurodegenerative disease ecosystem and the strategies shaping the next generation of therapeutic innovation.
SpeakersMónica Povedano, Hospital Univ. Bellvitge, Neurology Service, TBC
Quimatryx, TBA
BMS?
